Outcome of Annual General Meeting of March 27, 2014

Approval of issuance of 600,000 shares reserved to Novo Nordisk A/S as contemplated by the agreement on NKG2A checkpoint inhibitor acquisition by Innate Pharma

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that during its Annual General Meeting (“AGM”) which took place on March 27, 2014, in Marseille, France, a number of 26,571,573 votes were expressed out of a total of 46,104,742 shares with voting rights, representing a quorum of 57.63%.

The resolution pertaining to the capital increase reserved to Novo Nordisk A/S as contemplated by the agreement regarding the acquisition by Innate Pharma of the NKG2A checkpoint inhibitor (see press release of February 5th, 2014) was approved. 600,000 new shares will be issued in the coming days to Novo Nordisk A/S.

Details of the votes are available on the Company’s website, in the investors’ room (www.innate-pharma.com/en/AGMdocuments).